I've done a search.. here's what I've found, but first a comment:
Look at the players in this vaccine- deja vu?
For a rare disease- and one that's easily treated, there has been and is alot of money invested in patenting and marketing a sucessful vaccine.
There's got to be ALOT of money to be gained. Oh..and check out the details on Baxter Intn'l.
1) SEC INFO 1998-1999
North American Vaccine, Inc. (the "Company") signed a definitive Share Exchange Agreement dated as of November 17, 1999 to be acquired by Baxter International Inc. ("Baxter") in a taxable stock for stock transaction pursuant to a Plan of Arrangement under the Canada Business Corporations Act valued at approximately $390 million. http://www.secinfo.com/drDcf.611h.htm
2) October 27, 2002 - By VALERIE COTSALAS (NYTimes) - New York and Region QUOTE FROM ARTICLE IT'S just a coincidence that the research was done in one of the places where it might do the most good. But after 10 years of work, scientists at Brookhaven National Laboratory have fashioned a new Lyme disease vaccine that they hope will be on the market by the end of the decade. The active ingredient is called outer-surface protein A. But the vaccine, now being developed by Baxter Healthcare Corporation of Deerfield, Ill., doesn't have Food and Drug Administration approval or a commercial name. It hasn't even been tested on humans yet. ''It's still in the very early stages,'' said Deborah Spak, a Baxter spokeswoman. ''It would be five to seven years before there's a commercially available vaccine.''END QUOTE
NOTE of interest: Baxter Healthcare CorporationOne Baxter Parkway Deerfield, Illinois 60015 U.S.A. Phone: 847-948-2000. Baxter Healthcare Corporation is a branch of Baxter International, Inc. . ... www.biospace.com/company_profile.aspx?CompanyID=1793
The Center for Environmental Molecular Science (CEMS) at Stony Brook University invites applications from undergraduate students to participate in a summer research program. CEMS involves a collaboration between Stony Brook University and Brookhaven National Laboratory, both situated on eastern Long Island in New York. CEMS research is focused on understanding the mechanisms that govern the behavior of chemical contaminants in our environment. Selections begin March 31.
FROM THE CEMS website: CEMS is an Environmental Molecular Science Institute funded by the National Science Foundation and the U.S. Department of Energy, with support from Stony Brook University and Brookhaven National Laboratory http://cems.geo.sunysb.edu/ Posted by seibertneurolyme (Member # 6416) on :
Thanks for posting. We all need to be aware of the people who are involved in this .
Bea Seibert
Posted by lou (Member # 81) on :
Well, they better do something different this time; if it is just like the last OspA vaccine, it will have problems too.
I think GlaxoSmithKline has a lyme vaccine in the works too, maybe just for Europe?
Posted by on :